Cargando…

Inhaled therapy in cystic fibrosis: agents, devices and regimens

KEY POINTS: There have been significant advances in both inhalation medicines and delivery devices with “intelligent nebulisers” and “dry-powder inhalers” becoming commonplace in CF care. Inhaled medicines generate high levels of a drug within the airways with limited systemic effects, offering safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agent, Penny, Parrott, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487378/ https://www.ncbi.nlm.nih.gov/pubmed/26306111 http://dx.doi.org/10.1183/20734735.021014

Ejemplares similares

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis
por: Stanford, Gemma, et al.
Publicado: (2019)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
por: Daddario, Martha K, et al.
Publicado: (2010)

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives
por: Taccetti, Giovanni, et al.
Publicado: (2021)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis
por: Chorepsima, Stamatia, et al.
Publicado: (2018)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device
por: Elkins, Mark R., et al.
Publicado: (2014)

Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis
por: Xu, Meng-Jiao, et al.
Publicado: (2020)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Use of inhaled antibiotics among Danish patients with cystic fibrosis
por: Møller, Rikke, et al.
Publicado: (2022)

Gene therapy for the treatment of cystic fibrosis
por: Burney, Tabinda J, et al.
Publicado: (2012)

Strategies for the etiological therapy of cystic fibrosis
por: Maiuri, Luigi, et al.
Publicado: (2017)

Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate “normative adherence”
por: Hoo, Zhe Hui, et al.
Publicado: (2016)

High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans
por: Bartley, Bethany L., et al.
Publicado: (2020)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
por: Tejada, Sofia, et al.
Publicado: (2022)

Inhalation with Fucose and Galactose for Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients
por: Hauber, Hans-Peter, et al.
Publicado: (2008)

Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review
por: Kirkby, Stephen, et al.
Publicado: (2011)

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis
por: Li, Danni, et al.
Publicado: (2023)

Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies
por: Carbone, Annalucia, et al.
Publicado: (2023)

Lentiviral Vectors and Cystic Fibrosis Gene Therapy
por: Castellani, Stefano, et al.
Publicado: (2010)

Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis
por: Freswick, Peter N., et al.
Publicado: (2022)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review
por: Martínez-García, Miguel Ángel, et al.
Publicado: (2022)

The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches
por: Kłodzińska, Sylvia Natalie, et al.
Publicado: (2016)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Airway Clearance Therapy in Cystic Fibrosis Patients Insights from a Clinician Providing Cystic Fibrosis Care
por: Chaudary, Nauman, et al.
Publicado: (2021)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e3ct2a5nkeckspemshsp2oja9i